New Enterprise Associates made its first biotech investment in Europe last week by leading a €23 million ($29.7 million) third venture round for Prosensa B.V., the Dutch rare genetic diseases company.

For about 35 years, NEA has invested almost exclusively in the U.S. for biopharma, with a focus on hubs like Cambridge, Mass., and northern California.